Improving Patient Adherence and Quality
of Life in Hepatocellular Carcinoma (HCC): Anticipating and Managing
Treatment Related Adverse Events Associated with Emerging
Combination Regimens
A continuing medical education activity sponsored by NAMCP and AAMCN.
Novel Treatment Approaches in the
Management of Hepatocellular Carcinoma (HCC): What Managed Care
Needs to Know About Emerging Combination Regimens is a 3-part live
webinar series that will provide attendees with the latest
information in the management of HCC
This is Part 2 of the series focusing on improving clinical and
economic outcomes in HCC
This activity is an archive from the webinar held March 25, 2020
This activity is valid from April 1, 2020 to
April 1, 2022 |
Instructions for CME/CNE: Complete the pre-test, listen to the audio
and view the slides, complete the post test, complete the evaluation
form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your
internet browser without completing the post test, you will have ONE
more opportunity to complete. A score of 70% must be achieved on the
post test to receive continuing education credits. If you do not
pass the post test after two attempts, you will not be eligible to
try again. Once you complete the evaluation form and score 70% or
higher on your post test, you will automatically be given your
certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This presentation is supported by
educational grants from
Eisai and Merck & Co.
Description:
Hepatocellular carcinoma (HCC) is the most common type of liver
cancer, accounting for about 90% of cases of primary liver cancer in
the US. In 2019, it was expected that liver cancer accounted for
approximately 788,000 deaths globally, making it the second leading
cause of cancer-related deaths worldwide. Prognosis is especially
poor for those with unresectable HCC. Fortunately, new agents have
recently been approved that provide new options for clinicians in
the first-line setting. Additionally, targeted therapy and
immunotherapy combinations have shown improved efficacy and safety
in recent clinical trials. In this webinar series, attendees will
learn about the latest data necessary to make appropriate formulary
decisions and care for patients with HCC around these targeted and
immunotherapy combination options, especially as more are approved
and become available.
Upon completion of this
activity, participants will be able to:
-
Identify challenges to patient
adherence and quality of life in the use of targeted and
immunotherapeutic agents, and their combinations, in HCC
-
Examine adverse events commonly
associated with targeted therapies and immunotherapies, both
alone or in combination, used in HCC treatment
-
Explore strategies to monitor and
manage adverse events associated of emerging combination
regimens in HCC in order to improve patient adherence and
quality of life
-
Review recent clinical data around
the safety of targeted agents and immunotherapies and their
effect on patient quality of life
-
Assess how treatment strategies can
be affected by adverse events based on patient’s individualized
needs
Faculty: |
David Kaplan, MD
Associate Professor
Perelman School of Medicine
University of Pennsylvania |
Disclosure:
|
Dr. Kaplan
has served on an advisory board for Exelixis. He has
received grants or research support from Bayer
Healthcare, Inovio Pharmaceuticals, and Gilead Sciences.
His presentation has been peer reviewed for any bias. |
|
Planning Committee:
Bill Williams,
MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships
to disclose.
Will Williams has no relevant financial relationships to
disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in continuing
nursing credit.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This presentation is supported by
educational grants from
Eisai and Merck & Co.
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |